Nuclear Medicine and Biology
Volume 37, Issue 4 , Pages 421-426, May 2010

[18F]FE@SUPPY and [18F]FE@SUPPY:2 — metabolic considerations

  • Daniela Haeusler

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
    • Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
    • The authors contributed equally.
  • ,
  • Lukas Nics

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
    • Department of Nutritional Sciences, University of Vienna, A-1090 Vienna, Austria
    • The authors contributed equally.
  • ,
  • Leonhard-Key Mien

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
    • Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
  • ,
  • Johanna Ungersboeck

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
    • Department of Inorganic Chemistry, University of Vienna, A-1090 Vienna, Austria
  • ,
  • Rupert R. Lanzenberger

      Affiliations

    • Department of Psychiatry and Psychotherapy, Medical University of Vienna, A-1090 Vienna, Austria
  • ,
  • Karem Shanab

      Affiliations

    • Department of Drug and Natural Product Synthesis, University of Vienna, A-1090 Vienna, Austria
  • ,
  • Karoline M. Sindelar

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
  • ,
  • Helmut Viernstein

      Affiliations

    • Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
  • ,
  • Karl-Heinz Wagner

      Affiliations

    • Department of Nutritional Sciences, University of Vienna, A-1090 Vienna, Austria
  • ,
  • Robert Dudczak

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
  • ,
  • Kurt Kletter

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
  • ,
  • Wolfgang Wadsak

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
    • Department of Inorganic Chemistry, University of Vienna, A-1090 Vienna, Austria
  • ,
  • Markus Mitterhauser

      Affiliations

    • Department of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria
    • Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, A-1090 Vienna, Austria
    • Hospital Pharmacy of the General Hospital of Vienna, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel.: +43 1 40400 1557; fax: +43 1 40400 1559.

Received 17 September 2009; received in revised form 17 December 2009; accepted 1 January 2010. published online 08 March 2010.

Abstract 

Introduction

Recently, [18F]FE@SUPPY and [18F]FE@SUPPY:2 were introduced as the first positron emission tomography (PET) tracers for the adenosine A3 receptor. Thus, aim of the present study was the metabolic characterization of the two adenosine A3 receptor PET tracers.

Methods

In vitro carboxylesterase (CES) experiments were conducted using incubation mixtures containing different concentrations of the two substrates, porcine CES and phosphate-buffered saline. Enzymatic reactions were stopped by adding acetonitrile/methanol (10:1) after various time points and analyzed by a high-performance liquid chromatography (HPLC) standard protocol. In vivo experiments were conducted in male wild-type rats; tracers were injected through a tail vein. Rats were sacrificed after various time points (n=3), and blood and brain samples were collected. Sample cleanup was performed by an HPLC standard protocol.

Results

The rate of enzymatic hydrolysis by CES demonstrated Michaelis–Menten constants in a micromolar range (FE@SUPPY, 20.15 μM, and FE@SUPPY:2, 13.11 μM) and limiting velocities of 0.035 and 0.015 μM/min for FE@SUPPY and FE@SUPPY:2, respectively. Degree of metabolism in blood showed the following: 15 min pi 47.7% of [18F]FE@SUPPY was intact compared to 33.1% of [18F]FE@SUPPY:2; 30 min pi 30.3% intact [18F]FE@SUPPY was found compared to 15.6% [18F]FE@SUPPY:2. In brain, [18F]FE@SUPPY:2 formed an early hydrophilic metabolite, whereas metabolism of [18F]FE@SUPPY was not observed before 30 min pi

Conclusion

Knowing that metabolism in rats is several times faster than in human, we conclude that [18F]FE@SUPPY should be stable for the typical time span of a clinical investigation. As a consequence, from a metabolic point of view, one would tend to decide in favor of [18F]FE@SUPPY.

Keywords: PET, Adenosine A3 receptor, Fluorine-18, SUPPY, Metabolism, Carboxylesterase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(10)00003-X

doi:10.1016/j.nucmedbio.2010.01.001

Refers to erratum:

  • [18F]FE@SUPPY and [18F]FE@SUPPY:2 — metabolic considerations

    Daniela Haeusler, Lukas Nics, Leonhard-Key Mien, Johanna Ungersboeck, Rupert R. Lanzenberger, Karem Shanab, Helmut Spreitzer, Karoline M. Sindelar, Helmut Viernstein, Karl-Heinz Wagner, Robert Dudczak, Kurt Kletter, Wolfgang Wadsak, Markus Mitterhauser
    Nuclear Medicine and Biology April 2011 (Vol. 38, Issue 3, Page 449)

Nuclear Medicine and Biology
Volume 37, Issue 4 , Pages 421-426, May 2010